Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

STOCKHOLM, Nov. 8, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs ...

According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...

In addition to his work at Inno-Spec, Oliver is actively involved in various industry associations, contributing to the growth and development of hyperspectral imaging applications. His commitment to ...

TOKYO, Nov 5, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai Innovation,Inc. has been selected as a ...

Election officials say the machines that count election ballots are running as they should in Sedgwick County. Officials tested the tabulators Friday morning. The IRS just announced big tax change ...

LONDON STOCK EXCHANGE ANNOUNCEMENT ...

Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than in the US.

For the drugmaker Eisai, the trial was a shot at a windfall — potentially billions of dollars — for defanging a disease that had confounded researchers for more than a century. To assess the ...

Future of Healthcategory Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest July 30, 2024 Businesscategory Shares of Japan's Eisai tumble after EU rejects ...

As early voting opened in Texas on Oct. 21, viral claims spread online alleging that ballot machines in Tarrant County — home of Fort Worth and one of the most populous counties in the state ...